ERBB2 and breast cancer: In contrast, in the acquired resistance HER2+ BC cell line (BT474R), the ectopically down-regulation of SALL4 decreased PI3K and AKT’s activation and upregulated PTEN expression, along with downregulation of BCL2 (Figure S2E).